MK-677 vs Ipamorelin
MK-677 and ipamorelin are frequently compared because both raise growth hormone through the same ghrelin receptor — but one is an oral small molecule and the other an injectable peptide. That shared mechanism is also why stacking them tends to be redundant. This comparison covers their pharmacology, dosing, and practical trade-offs as reported in research references.
| MK-677 | Ipamorelin | |
|---|---|---|
| Class | Oral non-peptide growth-hormone secretagogue (ibutamoren) | Injectable selective peptide GH secretagogue |
| Primary mechanism | Ghrelin-receptor (GHS-R) agonist; sustained GH/IGF-1 elevation | Ghrelin-receptor (GHS-R) agonist; pulsatile GH release |
| Molecule type / route | Small molecule, orally active — not a peptide, not injected | Peptide, subcutaneous injection |
| Reported half-life | Long, ~24 hours | Short, ~2 hours |
| Reported research dosing | ~10-25 mg once daily (oral) | ~100-300 mcg per dose, often 1-3x/day |
| Release pattern | Continuous, all-day elevation of GH/IGF-1 | Short, pulse-like release closer to the natural rhythm |
| Noted caveats / side effects | Increased appetite, water retention, possible reduced insulin sensitivity | Generally cleaner profile in references; injection required |
| Regulatory / anti-doping status | Not approved; research-use-only; WADA Prohibited (S2) | Not approved; research-use-only; WADA Prohibited (S2) |
MK-677
MK-677 (ibutamoren) is an orally active, non-peptide ghrelin-receptor agonist with a ~24-hour half-life that produces sustained all-day GH and IGF-1 elevation, at the cost of appetite, water-retention, and insulin-sensitivity caveats.
Full MK-677 profile →Ipamorelin
Ipamorelin is an injectable, selective peptide that hits the same ghrelin receptor but with a short ~2-hour action, giving a cleaner, more pulse-like GH release.
Full Ipamorelin profile →The bottom line
MK-677 and ipamorelin act on the same ghrelin receptor, so they are more alternatives than partners — MK-677 offers oral convenience and sustained elevation, while ipamorelin offers a shorter, more pulsatile profile by injection. Because they share a mechanism, research references generally consider stacking them redundant. Both are research-use-only, unapproved, and prohibited in sport; this is educational information, not medical advice.
Educational summary only. Dosing and effects describe how these compounds appear in the research literature — not a recommendation for human use. For laboratory research use only.
MK-677 vs Ipamorelin FAQ
What is the difference between MK-677 and ipamorelin?
MK-677 (ibutamoren) is an orally active, non-peptide molecule with a ~24-hour half-life that keeps GH and IGF-1 elevated all day, while ipamorelin is an injectable peptide with a ~2-hour action that produces a shorter, more pulse-like GH release. Both act on the same ghrelin receptor.
Is MK-677 better than ipamorelin?
Neither is objectively ‘better’ — they suit different goals. MK-677 is convenient (oral, once-daily, sustained) but carries appetite, water-retention, and insulin-sensitivity caveats, whereas ipamorelin gives a cleaner, more natural pulse but must be injected. Both are unapproved and research-use-only, so this is not medical advice.
Can you take MK-677 and ipamorelin together?
Because both stimulate the same ghrelin receptor (GHS-R), combining them is generally considered redundant rather than synergistic — you are pushing the same pathway twice. There is no controlled human data supporting the combination, and both are research-use-only; this is not a recommendation.
Is MK-677 a peptide or a SARM?
Neither. MK-677 is often grouped with research compounds and sometimes mislabeled a SARM, but it is actually a non-peptide ghrelin-receptor agonist (a growth-hormone secretagogue). It is not a selective androgen receptor modulator, and it is not a peptide despite frequently being sold alongside them.